Virbac has been growing earnings at an average annual rate of 1.3%, while the Pharmaceuticals industry saw earnings growing at 10.7% annually. Revenues have been growing at an average rate of 8.7% per year. Virbac's return on equity is 13.4%, and it has net margins of 10.3%.
Key information
1.31%
Earnings growth rate
1.52%
EPS growth rate
Pharmaceuticals Industry Growth
5.95%
Revenue growth rate
8.70%
Return on equity
13.37%
Net Margin
10.30%
Next Earnings Update
17 Sep 2026
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Virbac makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
OTCPK:VRBC.F Revenue, expenses and earnings (EUR Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Dec 25
1,465
151
680
0
30 Sep 25
1,449
142
678
0
30 Jun 25
1,433
133
675
0
31 Mar 25
1,415
139
660
0
31 Dec 24
1,397
145
645
0
30 Sep 24
1,368
143
625
0
30 Jun 24
1,339
141
605
0
31 Mar 24
1,293
131
589
0
31 Dec 23
1,247
121
573
0
30 Sep 23
1,229
120
570
0
30 Jun 23
1,210
119
568
0
31 Mar 23
1,213
121
563
0
31 Dec 22
1,216
122
557
0
30 Sep 22
1,184
120
535
0
30 Jun 22
1,151
119
513
0
31 Mar 22
1,107
116
500
0
31 Dec 21
1,064
113
487
0
30 Sep 21
1,025
137
473
0
30 Jun 21
985
161
459
0
31 Mar 21
960
148
449
0
31 Dec 20
934
136
439
0
30 Sep 20
944
104
444
0
30 Jun 20
953
72
448
0
31 Mar 20
946
62
451
0
31 Dec 19
938
52
454
0
30 Sep 19
921
43
449
0
30 Jun 19
903
34
445
0
31 Mar 19
886
27
446
0
31 Dec 18
869
20
446
0
30 Sep 18
862
8
442
0
30 Jun 18
854
-4
438
0
31 Mar 18
858
-3
440
0
31 Dec 17
862
-3
442
0
30 Sep 17
871
16
444
0
30 Jun 17
879
35
446
0
31 Mar 17
876
35
449
0
31 Dec 16
872
35
452
0
30 Sep 16
861
30
459
0
30 Jun 16
850
26
466
0
31 Mar 16
851
18
463
0
31 Dec 15
853
9
460
0
30 Sep 15
846
21
441
0
Quality Earnings: VRBC.F has high quality earnings.
Growing Profit Margin: VRBC.F's current net profit margins (10.3%) are lower than last year (10.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VRBC.F's earnings have grown by 1.3% per year over the past 5 years.
Accelerating Growth: VRBC.F's earnings growth over the past year (3.9%) exceeds its 5-year average (1.3% per year).
Earnings vs Industry: VRBC.F earnings growth over the past year (3.9%) exceeded the Pharmaceuticals industry -4.8%.
Return on Equity
High ROE: VRBC.F's Return on Equity (13.4%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/12 11:26
End of Day Share Price
2026/05/12 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Virbac SA is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.